LINK WILLIAM J PHD 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Tarsus (TARS) Director William J. Link Sells Shares
What Happened William J. Link, Ph.D., a director of Tarsus Pharmaceuticals, sold a total of 12,500 shares in open-market transactions on March 16, 2026, generating aggregate proceeds of about $859,819. The sales broke down as: 3,629 shares at a reported weighted average price of $68.09 (proceeds $247,099), 8,378 shares at a reported weighted average price of $69.03 (proceeds $578,333), and 493 shares at a reported weighted average price of $69.75 (proceeds $34,387). These were sales (not purchases), typically considered routine cashing-out transactions.
Key Details
- Transaction date: March 16, 2026 (filed March 18, 2026).
- Lot details and price ranges:
- 3,629 shares — reported WA price $68.09; pooled sale prices ranged $67.60–$68.59 (F2).
- 8,378 shares — reported WA price $69.03; pooled sale prices ranged $68.64–$69.63 (F3).
- 493 shares — reported WA price $69.75; pooled sale prices ranged $69.68–$69.85 (F4).
- Total shares sold: 12,500; total reported proceeds: $859,819.
- Shares owned after transaction: not specified in the excerpt provided (see full Form 4 for post-transaction holdings).
- Notable footnote: Sales were effected automatically under a Rule 10b5-1 trading plan adopted September 8, 2025 (F1). The filer will provide a breakdown of shares sold at each price within the noted ranges upon request.
- Filing timeliness: no late-filing flag noted in the provided extract.
Context These were open-market sales under a pre-established 10b5-1 plan, which authorizes automatic trades according to a preset schedule or parameters; such sales are often routine and do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases by insiders can be more informative than routine sales, but reported sales are still useful to track ownership changes and insider liquidity.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-16$68.09/sh−3,629$247,099→ 125,203 total - Sale
Common Stock
[F1][F3]2026-03-16$69.03/sh−8,378$578,333→ 116,825 total - Sale
Common Stock
[F1][F4]2026-03-16$69.75/sh−493$34,387→ 116,332 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
- [F2]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $67.60 to $68.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $68.64 to $69.63. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $69.68 to $69.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.